Streetbeat News

ALPMY

Astellas Pharma Inc.

https://www.astellas.com/jp/

CEO

Kenji Yasukawa

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

9.73

Mkt cap

17B

Volume

3.6K

High

9.74

P/E Ratio

-44.18

52-wk high

13.14

Low

9.68

Div yield

0.05

52-wk low

9.05

The U.S. FDA has approved an expanded label for Astellas' IZERVAY, allowing dosing beyond 12 months for the treatment of geographic atrophy secondary to age-related macular degeneration. This provides more flexibility for physicians and patients.

Portfolio Pulse from

February 12, 2025 | 11:45 pm

Astellas Pharma Inc. announced changes to its management structure effective April 1, 2025, aiming to create and deliver value for patients.

Portfolio Pulse from

February 04, 2025 | 6:45 am

Axcelead DDP has entered into a drug discovery service agreement with Astellas to work on targeted protein degraders.

Portfolio Pulse from

December 26, 2024 | 1:45 am

Astellas Pharma U.S. has partnered with Desert Oasis Healthcare to pilot DIGITIVA, a digital health solution for heart failure management. This initiative marks the first implementation of DIGITIVA in a health system.

Portfolio Pulse from

November 20, 2024 | 6:15 pm

The article discusses whether value investors should consider buying Astellas Pharma (ALPMY) stock, focusing on the Zacks Rank system which emphasizes earnings estimates and revisions.

Portfolio Pulse from

November 12, 2024 | 4:00 pm

William Blair has initiated coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with an Outperform rating, highlighting the competitive edge of its drug Syfovre in the market for geographic atrophy secondary to age-related macular degeneration. Despite competition from Novartis' Fabhalta, Apellis' Empaveli has significant market opportunities in C3G and IC-MPGN. The analyst projects peak sales for Syfovre to reach $2.0 billion by 2030.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 6:57 pm

Takeda, Astellas, and SMBC have partnered to establish Ciconia Bioventures, a venture focused on early-stage drug discovery in Japan. This collaboration aims to drive innovation in the pharmaceutical sector.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 6:24 am

Astellas has announced the FDA listing of DIGITIVA, a non-invasive digital health solution for heart failure management, allowing patients to monitor their condition at home.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 7:21 am

The European Commission has approved Astellas' PADCEV in combination with KEYTRUDA for the first-line treatment of advanced urothelial cancer. This regimen has shown superiority over the traditional platinum-containing chemotherapy, based on positive results from the Phase 3 EV-302 trial.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 6:53 am

Astellas has initiated a Phase 3 trial for fezolinetant, targeting vasomotor symptoms in women with hormone receptor-positive breast cancer undergoing adjuvant endocrine therapy. The study, named HIGHLIGHT 1™, aims to address moderate to severe symptoms in patients with stage 0-3 cancer.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 7:15 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.